Search Results - "Fehn, Karen"

PubPharm (18)

1

Safety of axicabtagene ciloleucel for relapsed/refractory large B-cell lymphoma in an elderly intercity population

in: Bone marrow transplantation | (12.04.2021)

by Shapiro, L. | Mustafa, J. | Lombardo, A. | +22

2

Treatment of severe COVID-19 with convalescent plasma in Bronx, NYC

in: JCI insight | Vol. 6, No. 4 (2021)

by Yoon, H. | Bartash, R. | Gendlina, I. | +52

UpdateOf: medRxiv. 2020 Dec 04;:. - PMID 33300012

3

Case report of combination therapy with Azacytidine, Enasidenib and Venetoclax in primary refractory AML

in: Experimental hematology & oncology | Vol. 10, No. 1 (2021), p. 1

by Jasra, S. | Kazemi, M. | Shah, N. | +13

4

Treatment of Severe COVID-19 with Convalescent Plasma in the Bronx, NYC

enthalten in: bioRxiv.org | 2020

by Yoon, H. | Bartash, R. | Gendlina, I. | +52

5

Treatment of Severe COVID-19 with Convalescent Plasma in the Bronx, NYC

in: medRxiv : the preprint server for health sciences | (04.12.2020)

by Yoon, H. | Bartash, R. | Gendlina, I. | +52

UpdateIn: JCI Insight. 2021 Jan 21;:. - PMID 33476300

6

Axicabtagene ciloleucel CD19 CAR-T cell therapy results in high rates of systemic and neurologic remissions in ten patients with refractory large B cell lymphoma including two with HIV and viral hepatitis

in: Journal of hematology & oncology | Vol. 13, No. 1 (2020), p. 1

by Abbasi, A. | Peeke, S. | Shah, N. | +21

7

Axicabtagene ciloleucel CD19 CAR-T cell therapy results in high rates of systemic and neurologic remissions in ten patients with refractory large B cell lymphoma including two with HIV and viral hepatitis

enthalten in: Journal of hematology & oncology | 2020

by Abbasi, A. | Peeke, S. | Shah, N. | +21

8

Phase I Trial of Veliparib, a Poly ADP Ribose Polymerase Inhibitor, Plus Metronomic Cyclophosphamide in Metastatic HER2-negative Breast Cancer

in: Clinical breast cancer | Vol. 18, No. 1 (2018), p. e135-e142

by Anampa, J. | Chen, A. | Wright, J. | +5

9

A phase I-II study of the histone deacetylase inhibitor vorinostat plus sequential weekly paclitaxel and doxorubicin-cyclophosphamide in locally advanced breast cancer

in: Breast cancer research and treatment | Vol. 146, No. 1 (2014), p. 145-52

by Tu, Y. | Hershman, D. | Bhalla, K. | +13

10

A phase I-II study of the histone deacetylase inhibitor vorinostat plus sequential weekly paclitaxel and doxorubicin-cyclophosphamide in locally advanced breast cancer

enthalten in: Breast cancer research and treatment | 2014

by Tu, Y. | Hershman, D. | Bhalla, K. | +13